echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junshi Biosciences completes the first patient dosing in the JUPITER-15 study of toripalimab

    Junshi Biosciences completes the first patient dosing in the JUPITER-15 study of toripalimab

    • Last Update: 2022-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of February 10, Junshi Biotech announced that its product toripalimab (trade name: Tuoyi®, product code: JS001) combined with standard chemotherapy is used as a treatment for gastric or esophagogastric junction adenocarcinoma after radical resection.
    The Phase III clinical study of adjuvant therapy (hereinafter referred to as "JUPITER-15 study", NCT05180734) has completed the first patient dosing

    .

    The JUPITER-15 study is a randomized, double-blind, placebo-controlled, international multicenter Phase III clinical study conducted by Prof.
    Ji Jiafu from Peking University Cancer Hospital, Prof.
    Shen Lin from Peking University Cancer Hospital and Prof.
    Li Guoxin from Nanfang Hospital of Southern Medical University Led the lead, aiming to evaluate the clinical efficacy and safety of toripalimab versus placebo combined with standard chemotherapy as postoperative adjuvant therapy for patients with gastric or esophagogastric junction adenocarcinoma after radical resection.
    It plans to enroll 680 patients.
    More than 60 research centers are involved

    .
    This is the first large-scale international multi-center Phase III clinical study of a PD-1 inhibitor independently developed in China for adjuvant therapy in the field of gastric cancer with high incidence in Chinese

    .

    Toripalimab is the first domestically-produced monoclonal antibody targeting PD-1 approved for marketing in China.
    It has accumulated more than 30 clinical trials covering more than 15 indications in China, the United States, Southeast Asia and Europe.
    a clinical study

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.